TechBio & Digital Health Strategy Executive | Early Stage Investor | Host of the Austin Next Podcast
How does Austin look when comparing share of VC dollars across stages? The short answer: Pretty consistent with our overall position. The long answer: A surprise or two. No shock that the Bay Area dominates from Seed to Series C, capturing between 30% and 45% of market share. Austin ranks between 5th and 7th place, holding a 3% to 4% share across each stage, matching our overall position of 5th or 6th depending on the dataset. Notably, Austin's highest rank is at the Series C stage, which I wasn’t expecting. My guess is this is less about a surge in Austin’s late-stage investments and more about Seattle’s drop-off at this stage. Here’s how venture dollars in Austin are distributed by stage: Seed: 12% Series A: 32% Series B: 33% Series C: 23% For comparison, the Bay Area's distribution is: Seed: 12% Series A: 26% Series B: 32% Series C: 30% Given the size of the rounds, it's logical that later stages command a larger share of total capital. To ascend to the next tier, Austin needs more companies to have both the demand for late stage funding and be able to secure it. 🙏 A big thanks to Peter Walker and Carta for continually providing such insightful data. What’s Next?
Texas continues to punch below it's weight. When you normalize for the size of the state's economies vs. the $'s invested statewide, Texas is somewhere around 20th. CA is killing it, as is MA. TX is behind Deleware, Wyoming, et. al.
TechBio & Digital Health Strategy Executive | Early Stage Investor | Host of the Austin Next Podcast
1moMike Krenn, Neal Bloom, Fred Grier, so San Diego in this analysis really confuses me. Is it just that the biotech first rounds are so large they are mostly falling into A and you have less traditional seed? Is it just Carta not getting a lot of the Seed stage deals in San Diego?